BeiGene, Ltd. Asset Resilience Ratio
BeiGene, Ltd. asset resilience ratio. BeiGene, Ltd. (ONC) has an Asset Resilience Ratio of 0.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can BeiGene, Ltd. fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BeiGene, Ltd. (2014–2023)
Asset resilience ratio of BeiGene, Ltd. from 2014 to 2023. This chart shows how BeiGene, Ltd.'s Asset Resilience Ratio has changed over time. Read BeiGene, Ltd. total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BeiGene, Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of BeiGene, Ltd..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: BeiGene, Ltd. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
BeiGene, Ltd. Industry Peers by Asset Resilience Ratio
Compare BeiGene, Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
BeiGene, Ltd. Asset Resilience Ratio by Year (2014–2023)
BeiGene, Ltd. asset resilience ratio by year from 2014 to 2023. The table below shows the annual Asset Resilience Ratio data for BeiGene, Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.04% | $2.60 Million | $5.81 Billion | -10.38pp |
| 2022-12-31 | 10.43% | $665.25 Million | $6.38 Billion | -15.84pp |
| 2021-12-31 | 26.27% | $2.24 Billion | $8.54 Billion | -32.10pp |
| 2020-12-31 | 58.36% | $3.27 Billion | $5.60 Billion | +35.74pp |
| 2019-12-31 | 22.62% | $364.73 Million | $1.61 Billion | -24.87pp |
| 2018-12-31 | 47.50% | $1.07 Billion | $2.25 Billion | -9.64pp |
| 2017-12-31 | 57.14% | $597.91 Million | $1.05 Billion | -12.02pp |
| 2016-12-31 | 69.16% | $280.66 Million | $405.81 Million | -1.60pp |
| 2015-12-31 | 70.76% | $82.62 Million | $116.76 Million | +13.88pp |
| 2014-12-31 | 56.88% | $30.50 Million | $53.62 Million | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more